• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用几何数据科学解锁多维癌症治疗方法。

Unlocking multidimensional cancer therapeutics using geometric data science.

机构信息

Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.

Warwick Cancer Research Centre, University of Warwick, Coventry, UK.

出版信息

Sci Rep. 2023 May 22;13(1):8255. doi: 10.1038/s41598-023-34853-x.

DOI:10.1038/s41598-023-34853-x
PMID:37217528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10202902/
Abstract

Personalised approaches to cancer therapeutics primarily involve identification of patient sub-populations most likely to benefit from targeted drugs. Such a stratification has led to plethora of designs of clinical trials that are often too complex due to the need for incorporating biomarkers and tissue types. Many statistical methods have been developed to address these issues; however, by the time such methodology is available research in cancer has moved on to new challenges and therefore in order to avoid playing catch-up it is necessary to develop new analytic tools alongside. One of the challenges facing cancer therapy is to effectively and appropriately target multiple therapies for sensitive patient population based on a panel of biomarkers across multiple cancer types, and matched future trial designs. We present novel geometric methods (mathematical theory of hypersurfaces) to visualise complex cancer therapeutics data as multidimensional, as well as geometric representation of oncology trial design space in higher dimensions. The hypersurfaces are used to describe master protocols, with application to a specific example of a basket trial design for melanoma, and thus setup a framework for further incorporating multi-omics data as multidimensional therapeutics.

摘要

个性化癌症治疗方法主要涉及确定最有可能从靶向药物中受益的患者亚群。这种分层导致了大量临床试验设计,由于需要纳入生物标志物和组织类型,这些设计往往过于复杂。已经开发了许多统计方法来解决这些问题;然而,当这种方法可用时,癌症研究已经进入了新的挑战,因此为了避免追赶,有必要同时开发新的分析工具。癌症治疗面临的挑战之一是如何针对多种疗法进行有效和适当的靶向治疗,这些疗法针对的是基于多个癌症类型的生物标志物面板的敏感患者群体,并匹配未来的试验设计。我们提出了新的几何方法(超曲面数学理论),将复杂的癌症治疗数据可视化多维,以及肿瘤学试验设计空间在更高维度的几何表示。超曲面用于描述主方案,应用于黑色素瘤篮子试验设计的特定示例,从而为进一步将多组学数据作为多维治疗方法纳入建立了一个框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/19a0fb76e166/41598_2023_34853_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/dbb433ce3e88/41598_2023_34853_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/7cf04a4a0671/41598_2023_34853_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/bbf6add3d82c/41598_2023_34853_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/6d68876e6442/41598_2023_34853_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/bfbf0935250b/41598_2023_34853_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/19a0fb76e166/41598_2023_34853_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/dbb433ce3e88/41598_2023_34853_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/7cf04a4a0671/41598_2023_34853_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/bbf6add3d82c/41598_2023_34853_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/6d68876e6442/41598_2023_34853_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/bfbf0935250b/41598_2023_34853_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19ef/10202902/19a0fb76e166/41598_2023_34853_Fig6_HTML.jpg

相似文献

1
Unlocking multidimensional cancer therapeutics using geometric data science.利用几何数据科学解锁多维癌症治疗方法。
Sci Rep. 2023 May 22;13(1):8255. doi: 10.1038/s41598-023-34853-x.
2
Definitions and statistical properties of master protocols for personalized medicine in oncology.肿瘤个性化医疗主方案的定义及统计学特性
J Biopharm Stat. 2018;28(2):217-228. doi: 10.1080/10543406.2017.1372778. Epub 2017 Oct 9.
3
New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.精准医学时代的新型临床试验设计:定义、优势、劣势及在肿瘤学中的应用概述。
Cancer Treat Rev. 2019 Feb;73:20-30. doi: 10.1016/j.ctrv.2018.12.003. Epub 2018 Dec 11.
4
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view.改进研究设计以扩大个性化肿瘤学的治疗选择:多方利益相关者的观点
Eur J Cancer. 2023 Nov;194:113278. doi: 10.1016/j.ejca.2023.113278. Epub 2023 Aug 4.
5
An overview of precision oncology basket and umbrella trials for clinicians.精准肿瘤篮子和伞式试验概述——临床医生视角
CA Cancer J Clin. 2020 Mar;70(2):125-137. doi: 10.3322/caac.21600. Epub 2020 Feb 7.
6
Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials.篮子试验和伞式试验设计中的统计学和后勤学考虑。
Cancer J. 2019 Jul/Aug;25(4):254-263. doi: 10.1097/PPO.0000000000000384.
7
The New NCI Precision Medicine Trials.美国国家癌症研究所的新精准医学临床试验
Clin Cancer Res. 2023 Dec 1;29(23):4728-4732. doi: 10.1158/1078-0432.CCR-23-0917.
8
Innovative trial design in precision oncology.精准肿瘤学中的创新试验设计。
Semin Cancer Biol. 2022 Sep;84:284-292. doi: 10.1016/j.semcancer.2020.09.006. Epub 2020 Oct 3.
9
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design.肿瘤不可知篮子到 N-of-1 平台试验和真实世界数据:改变精准肿瘤临床试验设计。
Cancer Treat Rev. 2024 Apr;125:102703. doi: 10.1016/j.ctrv.2024.102703. Epub 2024 Mar 4.
10
Challenges and approaches to implementing master/basket trials in oncology.肿瘤学中实施主/篮子试验的挑战与方法。
Blood Adv. 2019 Jul 23;3(14):2237-2243. doi: 10.1182/bloodadvances.2019031229.

本文引用的文献

1
Harnessing multimodal data integration to advance precision oncology.利用多模态数据整合推进精准肿瘤学。
Nat Rev Cancer. 2022 Feb;22(2):114-126. doi: 10.1038/s41568-021-00408-3. Epub 2021 Oct 18.
2
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling.单细胞分析揭示的异质性肿瘤微环境泛癌蓝图。
Cell Res. 2020 Sep;30(9):745-762. doi: 10.1038/s41422-020-0355-0. Epub 2020 Jun 19.
3
Next-generation characterization of the Cancer Cell Line Encyclopedia.下一代癌症细胞系百科全书的特征描述。
Nature. 2019 May;569(7757):503-508. doi: 10.1038/s41586-019-1186-3. Epub 2019 May 8.
4
On the need to adjust for multiplicity in confirmatory clinical trials with master protocols.关于在采用主方案的确证性临床试验中对多重性进行调整的必要性。
Ann Oncol. 2019 Apr 1;30(4):506-509. doi: 10.1093/annonc/mdz038.
5
Definitions and statistical properties of master protocols for personalized medicine in oncology.肿瘤个性化医疗主方案的定义及统计学特性
J Biopharm Stat. 2018;28(2):217-228. doi: 10.1080/10543406.2017.1372778. Epub 2017 Oct 9.
6
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.用于研究多种疗法、多种疾病或两者兼有的主方案。
N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062.
7
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.临床研究中的统计学争议:篮子试验、伞式试验和其他主方案:综述和实例。
Ann Oncol. 2017 Jan 1;28(1):34-43. doi: 10.1093/annonc/mdw413.
8
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.国家肺部基质试验:将晚期非小细胞肺癌分层生物学转化应用
Ann Oncol. 2015 Dec;26(12):2464-9. doi: 10.1093/annonc/mdv394. Epub 2015 Sep 25.
9
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.维莫非尼用于治疗伴有BRAF V600突变的多种非黑色素瘤癌症。
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
10
Biomarker based clinical trial design.基于生物标志物的临床试验设计。
Chin Clin Oncol. 2014 Sep;3(3):39. doi: 10.3978/j.issn.2304-3865.2014.02.03.